Longitudinal antigenic sequences and sites from intra-host evolution (LASSIE) identifies immune-selected HIV variants

Viruses

Volumn 7, Issue 10, 2015, Pages 5443-5475

  Hraber, Peter ^a   Korber, Bette ^a   Wagh, Kshitij ^a   Giorgi, Elena E ^a   Bhattacharya, Tanmoy ^a,b   Gnanakaran, S ^a   Lapedes, Alan S ^a   Learn, Gerald H ^c   Kreider, Edward F ^c   Li, Yingying ^c   Shaw, George M ^c   Hahn, Beatrice H ^c   Montefiori, David C ^d   Alam, S Munir ^d   Bonsignori, Mattia ^d   Moody, M Anthony ^d   Liao, Hua Xin ^d   Gao, Feng ^d   Haynes, Barton F ^d  

^a LOS ALAMOS NATIONAL LABORATORY   (United States)

^b SANTA FE INSTITUTE   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antigenic swarm; Coevolution; Envelope glycoprotein; Human immunodeficiency virus type 1; Immune escape; Immunogen design; Neutralizing antibodies; Quasispecies; Selection; Vaccine

Indexed keywords

ANTIGEN; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; VACCINE; VIRUS GLYCOPROTEIN; VIRUS ANTIGEN;

ARTICLE; COEVOLUTION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE SEQUENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE ESCAPE; IMMUNE RESPONSE; IMMUNOLOGY; INFECTION; MUTATION; PHYLOGENY; POLYMERASE CHAIN REACTION; VIRUS ENVELOPE; CLASSIFICATION; GENETIC SELECTION; GENETIC VARIATION; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE EVASION; ISOLATION AND PURIFICATION; LONGITUDINAL STUDY; PROCEDURES; VIROLOGY;

ANTIGENS, VIRAL; GENETIC VARIATION; HIV; HIV INFECTIONS; HUMANS; IMMUNE EVASION; LONGITUDINAL STUDIES; SELECTION, GENETIC; VIROLOGY;

EID: 84944907020     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v7102881     Document Type: Article

References (99)

1. Plotkin, S.A. Correlates of vaccine-induced immunity. Clin. Infect. Dis. 2008, 47, 401-409. [CrossRef] [PubMed]
2. Mascola, J.M.; Montefiori, D.M. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 2010, 28, 413-444. [CrossRef] [PubMed]
3. Mascola, J.R.; Lewis, M.G.; Stiegler, G.; Harris, D.; VanCott, T.C.; Hayes, D.; Louder, M.K.; Brown, C.R.; Sapan, C.V.; Frankel, S.S.; et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 1999, 73, 4009-4018. [PubMed]
4. Moldt, B.; Rakasz, E.G.; Schultz, N.; Chan-Hui, P.Y.; Swiderek, K.; Weisgrau, K.L.; Piaskowski, S.M.; Bergman, Z.; Watkins, D.I.; Poignard, P.; et al. Highly potent HIV-specific antibody neutralization in vitro translates into effective protection against mucosal SHIV challenge in vivo. Proc. Natl. Acad. Sci. USA 2012, 109, 18921-18925. [PubMed]
5. Keele, B.; Giorgi, E.; Salazar-Gonzalez, J.; Decker, J.; Pham, K.; Salazar, M.; Sun, C.; Grayson, T.; Wang, S.; Li, H.; et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 2008, 105, 7552-7557. [CrossRef] [PubMed]
6. Giorgi, E.; Funkhouser, B.; Athreya, G.; Perelson, A.; Korber, B.; Bhattacharya, T. Estimating time since infection in early homogeneous HIV-1 samples using a Poisson model. BMC Bioinformatics 2010, 11, 532. [CrossRef] [PubMed]
7. Mellors, J.W.; Rinaldo, C.R., Jr.; Gupta, P.; White, R.M.; Todd, J.A.; Kingsley, L.A. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996, 272, 1167-1170. [CrossRef] [PubMed]
8. Mackelprang, R.D.; Carrington, M.; Thomas, K.K.; Hughes, J.P.; Baeten, J.M.;Wald, A.; Farquhar, C.; Fife, K.; Campbell, M.S.; Kapiga, S.; et al. Host genetic and viral determinants of HIV-1 RNA set point among HIV-1 seroconverters from sub-Saharan Africa. J. Virol. 2015, 89, 2104-2111. [CrossRef] [PubMed]
9. Wolinsky, S.M.; Korber, B.T.; Neumann, A.U.; Daniels, M.; Kunstman, K.J.; Whetsell, A.J.; Furtado, M.R.; Cao, Y.; Ho, D.D.; Safrit, J.T. Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science 1996, 272, 537-542. [CrossRef] [PubMed]
10. Weiss, R.; Clapham, P.; Weber, J.; Dalgleish, A.; Lasky, L.; Berman, P. Variable and conserved neutralization antigens of human immunodeficiency virus. Nature 1986, 324, 572-575. [CrossRef] [PubMed]
11. Richman, D.D.;Wrin, T.; Little, S.J.; Petropoulos, C.J. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc. Natl. Acad. Sci. USA 2002, 100, 4144-4149. [CrossRef] [PubMed]
12. Wei, X.; Decker, J.M.; Wang, S.; Hui, H.; Kappes, J.C.; Wu, X.; Salazar-Gonzalez, J.F.; Salazar, M.G.; Kilby, J.M.; Saag, M.S.; et al. Antibody neutralization and escape by HIV-1. Nature 2003, 422, 307-312. [CrossRef] [PubMed]
13. Scheid, J.F.; Mouquet, H.; Feldhahn, N.; Seaman, M.S.; Velinzon, K.; Pietzsch, J.; Ott, R.G.; Anthony, R.M.; Zebroski, H.; Hurley, A.; et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009, 458, 636-640. [CrossRef] [PubMed]
14. Bar, K.J.; Tsao, C.-y.; Iyer, S.S.; Decker, J.M.; Yang, Y.; Bonsignori, M.; Chen, X.; Hwang, K.-K.; Montefiori, D.C.; Liao, H.-X.; et al. Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS Pathog. 2012, 8, e1002721. [CrossRef] [PubMed]
15. Liao, H.X.; Lynch, R.; Zhou, T.; Gao, F.; Alam, S.M.; Boyd, S.D.; Fire, A.Z.; Roskin, K.M.; Schramm, C.A.; Zhang, Z.; et al. Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 2013, 496, 469-476. [CrossRef] [PubMed]
16. Gao, F.; Bonsignori, M.; Liao, H.X.; Kumar, A.; Xia, S.M.; Lu, X.; Cai, F.; Hwang, K.K.; Song, H.; Zhou, T.; et al. Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies. Cell 2014, 158, 481-491. [CrossRef] [PubMed]
17. Hraber, P.; Seaman, M.S.; Bailer, R.T.; Mascola, J.R.; Montefiori, D.C.; Korber, B.T. Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection. AIDS 2014, 28, 163-169. [CrossRef] [PubMed]
18. Doria-Rose, N.A.; Schramm, C.A.; Gorman, J.; Moore, P.L.; Bhiman, J.N.; DeKosky, B.J.; Ernandes, M.J.; Georgiev, I.S.; Kim, H.J.; Pancera, M.; et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 2014, 509, 55-62. [CrossRef] [PubMed]
19. Goonetilleke, N.; Liu, M.; Salazar-Gonzalez, J.; Ferrari, G.; Giorgi, E.; Ganusov, V.; Keele, B.; Learn, G.; Turnbull, E.; Salazar, M.; et al. The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. J. Exp. Med. 2009, 206, 1253-1272. [CrossRef] [PubMed]
20. Fischer, W.; Ganusov, V.V.; Giorgi, E.E.; Hraber, P.T.; Keele, B.F.; Leitner, T.; Han, C.S.; Gleasner, C.D.; Green, L.; Lo, C.C.; et al. Transmission of single HIV-1 genomes and dynamics of early immune escape revealed by ultra-deep sequencing. PLoS ONE 2010, 5, e12303. [CrossRef] [PubMed]
21. Liu, M.K.; Hawkins, N.; Ritchie, A.J.; Ganusov, V.V.; Whale, V.; Brackenridge, S.; Li, H.; Pavlicek, J.W.; Cai, F.; Rose-Abrahams, M.; et al. Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J. Clin. Invest. 2013, 123, 380-393. [PubMed]
22. Frost, S.D.; Wrin, T.; Smith, D.M.; Kosakovsky Pond, S.L.; Liu, Y.; Paxinos, E.; Chappey, C.; Galovich, J.; Beauchaine, J.; Petropoulos, C.J.; et al. Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc. Natl. Acad. Sci. USA 2005, 102, 18514-18519. [CrossRef] [PubMed]
23. Edwards, C.T.; Holmes, E.C.; Pybus, O.G.; Wilson, D.J.; Viscidi, R.P.; Abrams, E.J.; Phillips, R.E.; Drummond, A.J. Evolution of the human immunodeficiency virus envelope gene is dominated by purifying selection. Genetics 2006, 174, 1441-1453. [CrossRef] [PubMed]
24. Poon, A.F.; Kosakovsky Pond, S.L.; Bennett, P.; Richman, D.D.; Leigh Brown, A.J.; Frost, S.D. Adaptation to human populations is revealed by within-host polymorphisms in HIV-1 and hepatitis C virus. PLoS Pathog. 2007, 3, e45. [CrossRef] [PubMed]
25. Walker, L.M.; Phogat, S.K.; Chan-Hui, P.Y.;Wagner, D.; Phung, P.; Goss, J.L.;Wrin, T.; Simek, M.D.; Fling, S.; Mitcham, J.L.; et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326, 285-289. [CrossRef] [PubMed]
26. Wu, X.; Yang, Z.Y.; Li, Y.; Hogerkorp, C.M.; Schief, W.R.; Seaman, M.S.; Zhou, T.; Schmidt, S.D.; Wu, L.; Xu, L.; et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010, 329, 856-861. [CrossRef] [PubMed]
27. Walker, L.M.; Huber, M.; Doores, K.J.; Falkowska, E.; Pejchal, R.; Julien, J.P.; Wang, S.K.; Ramos, A.; Chan-Hui, P.Y.; Moyle, M.; et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 2011, 477, 466-470. [CrossRef] [PubMed]
28. Scheid, J.F.; Mouquet, H.; Ueberheide, B.; Diskin, R.; Klein, F.; Oliveira, T.Y.; Pietzsch, J.; Fenyo, D.; Abadir, A.; Velinzon, K.; et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 2011, 333, 1633-1637. [CrossRef] [PubMed]
29. Kepler, T.B. Reconstructing a B-cell clonal lineage. I. Statistical inference of unobserved ancestors. F1000Res 2013, 2, 103. [CrossRef] [PubMed]
30. Kepler, T.B.; Munshaw, S.; Wiehe, K.; Zhang, R.; Yu, J.S.; Woods, C.W.; Denny, T.N.; Tomaras, G.D.; Alam, S.M.; Moody, M.A.; et al. Reconstructing a B-cell clonal lineage. II. Mutation, selection, and affinity maturation. Front. Immunol. 2014, 5, e170. [CrossRef] [PubMed]
31. Wibmer, C.K.; Bhiman, J.N.; Gray, E.S.; Tumba, N.; Abdool Karim, S.S.; Williamson, C.; Morris, L.; Moore, P.L. Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes. PLoS Pathog. 2013, 9, e1003738. [CrossRef] [PubMed]
32. Haynes, B.F.; McElrath, M.J. Progress in HIV-1 vaccine development. Curr. Opin. HIV AIDS 2013, 8, 326-332. [CrossRef] [PubMed]
33. Haynes, B.F.; Moody, M.A.; Alam, S.M.; Bonsignori, M.; Verkoczy, L.; Ferrari, G.; Gao, F.; Tomaras, G.D.; Liao, H.X.; Kelsoe, G. Progress in HIV-1 vaccine development. J. Allergy Clin. Immunol. 2014, 134, 3-10. [CrossRef] [PubMed]
34. Tomaras, G.D.; Haynes, B.F. HIV-1-specific antibody responses during acute and chronic HIV-1 infection. Curr. Opin. HIV AIDS 2009, 4, 373-379. [CrossRef] [PubMed]
35. Mascola, J.M.; Haynes, B.F. HIV-1 neutralizing antibodies: Understanding nature's pathways. Immunol. Rev. 2013, 254, 225-244. [CrossRef] [PubMed]
36. Burton, D.; Mascola, J. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 2015, 16, 571-576. [CrossRef] [PubMed]
37. Haynes, B.F.; Kelsoe, G.; Harrison, S.C.; Kepler, T.B. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat. Biotechnol. 2012, 30, 423-433. [CrossRef] [PubMed]
38. Wu, X.; Zhang, Z.; Schramm, C.A.; Joyce, M.G.; Do Kwon, Y.; Zhou, T.; Sheng, Z.; Zhang, B.; O'Dell, S.; McKee, K.; et al. Maturation and diversity of the VRC01-antibody lineage over 15 years of chronic HIV-1 infection. Cell 2015, 161, 470-485. [CrossRef] [PubMed]
39. Bonsignori, M.; Hwang, K.K.; Chen, X.; Tsao, C.Y.; Morris, L.; Gray, E.; Marshall, D.J.; Crump, J.A.; Kapiga, S.H.; Sam, N.E.; et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 2011, 85, 9998-10009. [CrossRef] [PubMed]
40. Kwong, P.D.; Mascola, J.R. Human antibodies that neutralize HIV: Identification, structures, and B cell ontogenies. Immunity 2012, 37, 412-425. [CrossRef] [PubMed]
41. Moody, M.A.; Gao, F.; Gurley, T.C.; Amos, J.D.; Kumar, A.; Hora, B.; Marshall, D.J.; Whitesides, J.F.; Xia, S.M.; Parks, R.; et al. Strain-specific V3 and CD4 binding site antibodies constrain autologous HIV-1 to a neutralization-resistant phenotype. Cell Host Microbe 2015, 18, 354-362. [CrossRef] [PubMed]
42. Ganusov, V.; Goonetilleke, N.; Liu, M.; Ferrari, G.; Shaw, G.; McMichael, A.; Borrow, P.; Korber, B.; Perelson, A. Fitness costs and diversity of CTL response determine the rate of CTL escape during the acute and chronic phases of HIV infection. J. Virol. 2011, 85, 10518-10528. [CrossRef] [PubMed]
43. Batorsky, R.; Sergeev, R.A.; Rouzine, I.M. The route of HIV escape from immune response targeting multiple sites is determined by the cost-benefit tradeoff of escape mutations. PLoS Comput. Biol. 2014, 10, e1003878. [CrossRef] [PubMed]
44. Huang, W.; Haubold, B.; Hauert, C.; Traulsen, A. Emergence of stable polymorphisms driven by evolutionary games between mutants. Nat. Commun. 2012, 3, 919. [PubMed]
45. Korber, B.; Foley, B.; Leitner, T.; Kuiken, C.; Pillai, S.K.; Sodroski, J.G. Numbering positions in HIV relative to HXB2CG. In Human Retroviruses and AIDS 1998; Korber, B., Kuiken, C., Foley, B., Hahn, B.H., McCutchan, F., Mellors, J.W., Sodroski, J., Eds.; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory: Los Alamos, NM, USA, 1998; pp. III-102-III-111.
46. Wu, X.; Zhou, T.; Zhu, J.; Zhang, B.; Georgiev, I.; Wang, C.; Chen, X.; Longo, N.S.; Louder, M.; McKee, K.; et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 2011, 333, 1593-1602. [CrossRef] [PubMed]
47. West, A.P.; Scharf, L.; Horwitz, J.; Klein, F.; Nussenzweig, M.C.; Bjorkman, P.J. Computational analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope residues. Proc. Natl. Acad. Sci. USA 2013, 110, 10598-10603. [CrossRef] [PubMed]
48. Pancera, M.; Zhou, T.; Druz, A.; Georgiev, I.S.; Soto, C.; Gorman, J.; Huang, J.; Acharya, P.; Chuang, G.Y.; Ofek, G.; et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature 2014, 514, 455-461. [CrossRef] [PubMed]
49. Zhou, T.; Georgiev, I.; Wu, X.; Yang, Z.Y.; Dai, K.; Finzi, A.; Kwon, Y.D.; Scheid, J.F.; Shi, W.; Xu, L.; et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010, 329, 811-817. [CrossRef] [PubMed]
50. Diskin, R.; Scheid, J.F.; Marcovecchio, P.M.; West, A.P., Jr.; Klein, F.; Gao, H.; Gnanapragasam, P.N.; Abadir, A.; Seaman, M.S.; Nussenzweig, M.C.; et al. Increasing the potency and breadth of an HIV antibody by using structure-based rational design. Science 2011, 334, 1289-1293. [CrossRef] [PubMed]
51. Zhou, T.; Xu, L.; Dey, B.; Hessell, A.J.; Van Ryk, D.; Xiang, S.H.; Yang, X.; Zhang, M.Y.; Zwick, M.B.; Arthos, J.; et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007, 445, 732-737. [CrossRef] [PubMed]
52. Liao, H.X.; Bonsignori, M.; Alam, S.M.; McLellan, J.S.; Tomaras, G.D.; Moody, M.A.; Kozink, D.M.; Hwang, K.K.; Chen, X.; Tsao, C.Y.; et al. Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2. Immunity 2013, 38, 176-186. [CrossRef] [PubMed]
53. Fera, D.; Schmidt, A.G.; Haynes, B.F.; Gao, F.; Liao, H.X.; Kepler, T.B.; Harrison, S.C. Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains. Proc. Natl. Acad. Sci. USA 2014, 111, 10275-10280. [CrossRef] [PubMed]
54. HIV genome browser. Available online: hiv.lanl.gov/content/sequence/genome_browser/ browser.html (accessed on 13 October 2015).
55. CATNAP: Compile, analyze and tally NAb panels. Available online: hiv.lanl.gov/components/ sequence/HIV/neutralization/ (accessed on 13 October 2015).
56. Murrell, B.;Wertheim, J.O.; Moola, S.;Weighill, T.; Scheffler, K.; Kosakovsky Pond, S.L. Detecting individual sites subject to episodic diversifying selection. PLoS Genet. 2012, 8, e1002764. [CrossRef] [PubMed]
57. Kosakovsky Pond, S.L.; Frost, S.D. Not so different after all: A comparison of methods for detecting amino acid sites under selection. Mol. Biol. Evol. 2005, 22, 1208-1222. [CrossRef] [PubMed]
58. Crooks, G.E.; Hon, G.; Chandonia, J.M.; Brenner, S.E. WebLogo: A sequence logo generator. Genome Res. 2004, 14, 1188-1190. [CrossRef] [PubMed]
59. Schneider, T.D.; Stephens, R.M. Sequence logos: A new way to display consensus sequences. Nucleic Acids Res. 1990, 18, 6097-6100. [CrossRef] [PubMed]
60. Moore, P.L.; Gray, E.S.;Wibmer, C.K.; Bhiman, J.N.; Nonyane, M.; Sheward, D.J.; Hermanus, T.; Bajimaya, S.; Tumba, N.L.; Abrahams, M.R.; et al. Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 2012, 18, 1688-1692. [CrossRef] [PubMed]
61. Kong, L.; Lee, J.H.; Doores, K.J.; Murin, C.D.; Julien, J.P.; McBride, R.; Liu, Y.; Marozsan, A.; Cupo, A.; Klasse, P.J.; et al. Supersite of immune vulnerability on the glycosylated face of HIV-1 envelope glycoprotein gp120. Nat. Struct. Mol. Biol. 2013, 20, 796-803. [CrossRef] [PubMed]
62. Hartigan, J.A. Clustering Algorithms; Wiley: New York, 1975; p. 351.
63. Kaufman, L.; Rousseew, P.J. Finding groups in data: An introduction to cluster analysis; John Wiley and Sons: Hoboken, 2005; p. 342.
64. Pennings, P.S.; Kryazhimskiy, S.;Wakeley, J. Loss and recovery of genetic diversity in adapting populations of HIV. PLoS Genet. 2014, 10, e1004000. [PubMed]
65. Salazar-Gonzalez, J.; Salazar, M.; Keele, B.; Learn, G.; Giorgi, E.; Li, H.; Decker, J.; Wang, S.; Baalwa, J.; Kraus, M.; et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J. Exp. Med. 2009, 206, 1273-1289. [CrossRef] [PubMed]
66. Salazar-Gonzalez, J.F.; Bailes, E.; Pham, K.T.; Salazar, M.G.; Guffey, M.B.; Keele, B.F.; Derdeyn, C.A.; Farmer, P.; Hunter, E.; Allen, S.; et al. Deciphering human immunodeficiency virus type 1 transmission and early envelope diversification by single-genome amplification and sequencing. J. Virol. 2008, 82, 3952-3970. [CrossRef] [PubMed]
67. Palmer, S.; Kearney, M.; Maldarelli, F.; Halvas, E.K.; Bixby, C.J.; Bazmi, H.; Rock, D.; Falloon, J.; Davey, R.T.J.; Dewar, R.L.; et al. Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J. Clin. Microbiol. 2005, 43, 406-413. [CrossRef] [PubMed]
68. Henn, M.R.; Boutwell, C.L.; Charlebois, P.; Lennon, N.J.; Power, K.A.; Macalalad, A.R.; Berlin, A.M.; Malboeuf, C.M.; Ryan, E.M.; Gnerre, S.; et al. Whole genome deep sequencing of HIV-1 reveals the impact of early minor variants upon immune recognition during acute infection. PLoS Pathog. 2012, 8, e1002529. [CrossRef] [PubMed]
69. Maher, S.J.; Murray, J.M. The unrooted set covering connected subgraph problem differentiating between HIV envelope sequences. Eur. J. Oper. Res. 2016, 248, 668-680. [CrossRef]
70. Murray, J.M.; Moenne-Loccoz, R.; Velay, A.; Habersetzer, F.; Doffoël, M.; Gut, J.P.; Fofana, I.; Zeisel, M.B.; Stoll-Keller, F.; Baumert, T.F.; et al. Genotype 1 hepatitis C virus envelope features that determine antiviral response assessed through optimal covariance networks. PLoS ONE 2013, 8, e67254. [CrossRef] [PubMed]
71. Korber, B.; Gnanakaran, S. The implications of patterns in HIV diversity for neutralizing antibody induction and susceptibility. Curr. Opin. HIV AIDS 2009, 4, 408-417. [CrossRef] [PubMed]
72. Sather, D.N.; Carbonetti, S.; Malherbe, D.; Pissani, F.; Stuart, A.B.; Hessell, A.J.; Gray, M.D.; Mikell, I.; Kalams, S.A.; Haigwood, N.L.; et al. Emergence of broadly neutralizing antibodies and viral co-evolution in two subjects during the early stages of infection with human immunodeficiency virus type 1. J. Virol. 2014, 88, 12968-12981. [CrossRef] [PubMed]
73. Wang, S.; Mata-Fink, J.; Kriegsman, B.; Hanson, M.; Irvine, D.J.; Eisen, H.N.; Burton, D.R.; Wittrup, K.D.; Kardar, M.; Chakraborty, A.K. Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. Cell 2015, 160, 785-797. [CrossRef] [PubMed]
74. Malherbe, D.C.; Doria-Rose, N.A.; Misher, L.; Beckett, T.; Puryear,W.B.; Schuman, J.T.; Kraft, Z.; O'Malley, J.; Mori, M.; Srivastava, I.; et al. Sequential immunization with a subtype B HIV-1 envelope quasispecies partially mimics the in vivo development of neutralizing antibodies. J. Virol. 2011, 85, 5262-5274. [CrossRef] [PubMed]
75. Pissani, F.; Malherbe, D.C.; Robins, H.; DeFilippis, V.R.; Park, B.; Sellhorn, G.s.; Stamatatos, L.; Overbaugh, J.; Haigwood, N.L. Motif-optimized subtype A HIV envelope-based DNA vaccines rapidly elicit neutralizing antibodies when delivered sequentially. Vaccine 2012, 30, 5519-5526. [CrossRef] [PubMed]
76. Malherbe, D.C.; Pissani, F.; Sather, D.N.; Guo, B.; Pandey, S.; Sutton, W.F.; Stuart, A.B.; Robins, H.; Park, B.; Krebs, S.J.; et al. Envelope variants circulating as initial neutralization breadth developed in two HIV-infected subjects stimulate multiclade neutralizing antibodies in rabbits. J. Virol. 2014, 88, 12949-12967. [CrossRef] [PubMed]
77. McIlroy, D.; Barteau, B.; Cany, J.; Richard, P.; Gourden, C.; Conchon, S.; Pitard, B. DNA/amphiphilic block co-polymer nanospheres promote low-dose DNA vaccination. Mol. Ther. 2009, 17, 1473-1481. [CrossRef] [PubMed]
78. Chèvre, R.; Le Bihan, O.; Beilvert, F.; Chatin, B.; Barteau, B.; Mével, M.; Lambert, O.; Pitard, B. Amphiphilic block copolymers enhance the cellular uptake of DNA molecules through a facilitated plasma membrane transport. Nucleic Acids Res. 2011, 39, 1610-1622. [CrossRef] [PubMed]
79. Kuntzen, T.; Timm, J.; Berical, A.; Lewis-Ximenez, L.L.; Jones, A.; Nolan, B.; Schulze zur Wiesch, J.; Li, B.; Schneidewind, A.; Kim, A.Y.; et al. Viral sequence evolution in acute hepatitis C virus infection. J. Virol. 2007, 81, 11658-11668. [CrossRef] [PubMed]
80. Dowd, K.; Netski, D.; Wang, X.; Cox, A.; Ray, S. Selection pressure from neutralizing antibodies drives sequence evolution during acute infection with hepatitis C virus. Gastroenterology 2009, 136, 2377-2386. [CrossRef] [PubMed]
81. Liu, L.; Fisher, B.; Dowd, K.; Astemborski, J.; Cox, A.; Ray, S. Acceleration of hepatitis C virus envelope evolution in humans is consistent with progressive humoral immune selection during the transition from acute to chronic infection. J. Virol. 2010, 84, 5067-5077. [CrossRef] [PubMed]
82. Li, H.; Stoddard, M.B.; Wang, S.; Blair, L.M.; Giorgi, E.E.; Parrish, E.H.; Learn, G.H.; Hraber, P.; Goepfert, P.A.; Saag, M.S.; et al. Elucidation of hepatitis C virus transmission and early diversification by single genome sequencing. PLoS Pathog. 2012, 8, e1002880. [CrossRef] [PubMed]
83. Tarr, A.W.; Khera, T.; Hueging, K.; Sheldon, J.; Steinmann, E.; Pietschmann, T.; Brown, R.J. Genetic diversity underlying the envelope glycoproteins of hepatitis C virus: Structural and functional consequences and the implications for vaccine design. Viruses 2015, 7, 3995-4046. [CrossRef] [PubMed]
84. Nielsen, R.; Yang, Z. Likelihood models for detecting positively selected amino acid sites and applications to the HIV-1 envelope gene. Genetics 1998, 148, 929-936. [PubMed]
85. Pond, S.L.; Frost, S.D.; Grossman, Z.; Gravenor, M.B.; Richman, D.D.; Brown, A.J. Adaptation to different human populations by HIV-1 revealed by codon-based analyses. PLoS Comput. Biol. 2006, 2, e62. [CrossRef] [PubMed]
86. Eddy, S.R. Multiple alignment using hidden Markov models. ISMB 1995, 3, 114-120. [PubMed]
87. Gaschen, B.; Kuiken, C.; Korber, B.; Foley, B. Retrieval and on-the-fly alignment of sequence fragments from the HIV database. Bioinformatics 2001, 17, 415-418. [CrossRef] [PubMed]
88. Guindon, S.; Gascuel, O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum likelihood. Syst. Biol. 2003, 52, 696-704. [CrossRef] [PubMed]
89. Guindon, S.; Dufayard, J.F.; Lefort, V.; Anisimova, M.; Hordijk, W.; Gascuel, O. New algorithms and methods to estimate maximum-likelihood phylogenies: Assessing the performance of PhyML 3.0. Syst. Biol. 2010, 59, 307-321. [CrossRef] [PubMed]
90. Nickle, D.C.; Heath, L.; Jensen, M.A.; Gilbert, P.B.; Mullins, J.I.; Kosakovsky-Pond, S.L. HIV-specific probabilistic models of protein evolution. PLoS ONE 2007, 2, e503. [CrossRef] [PubMed]
91. Nemhauser, G.L.; Wolsey, L.A. Maximizing submodular functions: Formulations and analysis of algorithms. Ann. Discrete Math. 1981, 11, 279-301.
92. LASSIE repository. Available online: www.github.com/phraber/lassie (accessed on 13 October 2015).
93. Fischer,W. About the cover. In HIV Sequence Compendium 2011; Kuiken, C., Foley, B., Leitner, T., Apetrei, C., Hahn, B.H., Mizrachi, I., Mullins, J.I., Rambaut, A.,Wolinsky, S.M., Korber, B., Eds.; Theoretical Biology and Biophysics Group, Los Alamos National Laboratory: Los Alamos, NM, USA, 2011; pp. 2-3.
94. Brodin, J.; Krishnamoorthy, M.; Athreya, G.; Fischer, W.; Hraber, P.; Gleasner, C.; Green, L.; Korber, B.; Leitner, T. Amultiple-alignment based primer design algorithm for genetically highly variableDNAtargets. BMC Bioinformatics 2013, 14, 255. [CrossRef] [PubMed]
95. PixelGram repository. Available online: www.github.com/phraber/pixelgram (accessed on 13 October 2015).
96. Paradis, E.; Claude, J.; Strimmer, K. APE: Analyses of phylogenetics and evolution in R language. Bioinformatics 2004, 20, 289-290. [CrossRef] [PubMed]
97. Delport, W.; Poon, A.F.; Frost, S.D.; Kosakovsky Pond, S.L. Datamonkey 2010: A suite of phylogenetic analysis tools for evolutionary biology. Bioinformatics 2010, 26, 2455-2457. [CrossRef] [PubMed]
98. Lanave, C.; Preparata, G.; Saccone, C.; Serio, G. A new method for calculating evolutionary substitution rates. J. Mol. Evol. 1984, 20, 86-93. [CrossRef] [PubMed]
99. Tavaré, S. Some probabilistic and statistical problems in the analysis of DNA sequences. Lect. Math. Life Sci. 1986, 17, 57-86.